

DAVID Y. IGE
GOVERNOR

DOUGLAS S. CHIN
LIEUTENANT GOVERNOR

**STATE OF HAWAII
OFFICE OF THE DIRECTOR
DEPARTMENT OF COMMERCE AND CONSUMER AFFAIRS**

335 MERCHANT STREET, ROOM 310
P.O. BOX 541
HONOLULU, HAWAII 96809
Phone Number: 586-2850
Fax Number: 586-2856
cca.hawaii.gov

CATHERINE P. AWAKUNI COLÓN
DIRECTOR

JO ANN M. UCHIDA TAKEUCHI
DEPUTY DIRECTOR

TO THE HOUSE COMMITTEE ON
HEALTH AND HUMAN SERVICES

TWENTY-NINTH LEGISLATURE
Regular Session of 2018

Tuesday, March 13, 2018
8:30 a.m.

TESTIMONY ON SENATE BILL NO. 2199, S.D.1, RELATING TO INSURANCE.

TO THE HONORABLE JOHN M. MIZUNO, CHAIR, AND MEMBERS OF THE
COMMITTEE:

The Department of Commerce and Consumer Affairs (“Department”) appreciates the opportunity to testify in strong support of S.B. 2199, S.D. 1, Relating to Insurance. My name is Gordon Ito, and I am the Insurance Commissioner for the Department’s Insurance Division.


Section 1332 of the Patient Protection and Affordable Care Act (“ACA”) allows states to apply for a state innovation waiver to implement innovative ways to provide access to quality health care that is at least as comprehensive and affordable as would be provided absent the waiver, and to provide coverage to a comparable number of residents of the state as would be provided coverage absent a waiver.

Reinsurance programs in conjunction with section 1332 innovation waivers have been established in other states as a method to help mitigate premium increases in their individual health insurance markets. The waivers provide for “pass-through” funding from the federal government based on savings their reinsurance programs create. The

authority provided by this measure is necessary to allow the State to pursue a similar opportunity.

Thank you for the opportunity to testify in strong support of this measure.

DAVID Y. IGE
GOVERNOR



PANKAJ BHANOT
DIRECTOR

CATHY BETTS
DEPUTY DIRECTOR

STATE OF HAWAII
DEPARTMENT OF HUMAN SERVICES
P. O. Box 339
Honolulu, Hawaii 96809-0339

March 11, 2018

TO: The Honorable Representative John Mizuno, Chair
House Committee on Health and Human Services

FROM: Pankaj Bhanot, Director

SUBJECT: **SB 2199 SD1 – RELATING TO INSURANCE**

Hearing: Tuesday, March 13, 2018 8:30 a.m.
Conference Room 329, State Capitol

DEPARTMENT'S POSITION: The Department of Human Services (DHS) supports this bill.

PURPOSE: The purpose of the bill is to authorize the State to apply for and implement a waiver from certain provisions of the Patient Protection and Affordable Care Act of 2010, as amended. The Senate Committee on Ways & Means amended the measure by defecting the effective date and making technical amendments.

DHS participated in the Affordable Health Insurance Working Group that discussed the ever-increasing costs to our health care system which affect the affordability of our health insurance. One of the recommendations of the group was to submit another state innovation waiver proposal, known as a 1332 waiver, to the federal government for approval. The Department of Commerce and Consumer Affairs' Insurance Division will be lead on this effort.

Also, DHS Med-QUEST division will be submitting a Medicaid waiver renewal known as an 1115 waiver for continued innovations in the Medicaid program. These efforts complement and rely on each other to address the issues of a sustainable health insurance and health care delivery system for our community.

Thank you for the opportunity to testify on this measure.

AN EQUAL OPPORTUNITY AGENCY

Testimony of
Jonathan Ching
Government Relations Specialist

Before:
House Committee on Health & Human Services
The Honorable John M. Mizuno, Chair
The Honorable Bertrand Kobayashi, Vice Chair

March 13, 2018
8:30 a.m.
Conference Room 329

Re: SB2199 SD1, Relating to Insurance

Chair Mizuno, Vice-Chair Kobayashi, and committee members, thank you for this opportunity to provide testimony on SB2199 SD1, which authorizes the State to submit a section 1332 state innovation waiver proposal to the federal government and to implement the conditions of the waiver upon approval by the federal government.

Kaiser Permanente Hawaii SUPPORTS SB2199 SD1

As the committee is aware, significant uncertainties exist in the individual health insurance market. Last year, the federal government eliminated funding of Cost Sharing Reduction payments, which drove up premiums for many consumers seeking coverage in Hawai'i and across the nation. Both the elimination of the Cost Sharing Reduction payments and the elimination of the penalty associated with the individual mandate has resulted in further uncertainty about the future of the individual market. For this reason, we support the state's efforts to stabilize the individual market, including the creation of a statewide reinsurance program.

Although there is no solution as effective as an enforced individual mandate, an appropriately structured and funded reinsurance program is a step towards reducing individual premiums and promoting stability in the individual market. We saw the role the federal reinsurance program in partnership with risk adjustment played in supporting plans that enrolled higher-risk individuals, thereby protecting issuers against adverse selection within a market and encouraging them to offer products that serve all types of consumers. A state reinsurance program, if appropriately funded and structured, could support adequate levels of coverage while discouraging low-value plans. If appropriately structured, it could also benefit consumers by encouraging more health plan participation in markets where there isn't currently enough competition.

If appropriately and sustainably funded and structured, Kaiser Permanente Hawaii could support the implementation of a permanent, state-based reinsurance program in Hawai'i through a State

Innovation Waiver under Section 1332 of the Affordable Care Act (ACA). Similar to the transitional reinsurance program under ACA, we believe a state-based program should be claims-based since health plans have experience with the existing ACA framework. If implemented, the program should include a cap where federal risk adjustment starts (i.e. \$1 million in 2019), with a sufficiently high attachment point to encourage efficient claims management. We note that the Insurance Commissioner is in the process of retaining a third-party consultant to weigh various program design options.

In conclusion, to truly protect and preserve the individual market in Hawai'i, Kaiser Permanente Hawaii recommends that policymakers adopt a state-based individual mandate.

We look forward to having the opportunity to work with the Committee to further SB2199 SD1. Thank you for the opportunity to testify on this measure.



An Independent Licensee of the Blue Cross and Blue Shield Association

March 13, 2018

The Honorable John M. Mizuno, Chair
The Honorable Bertrand Kobayashi, Vice Chair
House Committee on Health and Human Services

Re: SB 2199, SD1 – Relating to Insurance

Dear Chair Mizuno, Vice Chair Kobayashi, and Members of the Committee:

The Hawaii Medical Service Association (HMSA) appreciates the opportunity to testify on SB 2199, SD1, that authorizes the State to apply for and implement a waiver from certain provisions of the Patient Protection and Affordable Care Act of 2010. HMSA supports SB 2199, SD1.

We understand this legislation to be a useful tool to allow the state to provide additional funding and innovative methods of pooling risk to cover health care for high-risk patients with costly medical claims. We look forward to the discussion on the details of the program including the funding mechanism.

Thank you for allowing us to testify on this measure.

Sincerely,

Pono Chong
Vice President, Government Relations

SB-2199-SD-1

Submitted on: 3/12/2018 8:10:58 AM

Testimony for HHS on 3/13/2018 8:30:00 AM

| Submitted By | Organization | Testifier Position | Present at Hearing |
|---------------------|--|---------------------------|---------------------------|
| Melodie Aduja | OCC Legislative Priorities Committee, Democratic Party of Hawai'i | Support | No |

Comments: